The role of some new factors in the pathophysiology of depression and cardiovascular disease: overview of recent research
Language English Country Sweden Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
18063922
PII: NEL280607A08
Knihovny.cz E-resources
- MeSH
- Autonomic Nervous System physiopathology MeSH
- Depressive Disorder complications physiopathology psychology MeSH
- Cardiovascular Diseases complications physiopathology psychology MeSH
- Humans MeSH
- Psychology MeSH
- Pituitary-Adrenal System physiopathology MeSH
- Hypothalamo-Hypophyseal System physiopathology MeSH
- Inflammation complications physiopathology psychology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Depressive disorders and cardiovascular disease are inter-connected by a whole range of pathophysiological mechanisms. Three biological mechanisms are fundamental: activation of the hypothalamus-hypohysis-adrenal axis with a subsequent increase in sympathetic-adrenal system activity, decrease in vagal tone with a decrease in heart rate variability, and alterations of thrombogenesis with increased platelet aggregability. Behavioural mechanisms and psycho-social factors are also integral to this common pathophysiology. Recently, research has focused mainly on studying various forms of stress, as well as changes and possibilities of influencing the autonomous vegetative system. Temporal aspects of the incidence and development of depressive episodes in relation to cardiovascular disease and subsequent cardiovascular morbidity and mortality are being studied, as well as general mortality risk factors. These findings are important for clinical practice. It is evident that in patients with untreated depressive disorder, the risk of developing cardiovascular disease is significantly higher than in patients suffering from a depressive disorder being treated with anti-depressants. From the data published so far, it may be surmised that depressive disorders in patients with cardiovascular disease may be reliably and safely treated with anti-depressants that act as inhibitors of serotonin re-uptake.